Olmesartan medoxomil tablets — Competitive Intelligence Brief

Olmesartan medoxomil tablets (Olmesartan medoxomil tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule

Target snapshot

Olmesartan medoxomil tablets (Olmesartan medoxomil tablets) — Lee's Pharmaceutical Limited. Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Olmesartan medoxomil tablets TARGET	Olmesartan medoxomil tablets	Lee's Pharmaceutical Limited	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Valsartan+/- Hydrochlorothiazide	Valsartan+/- Hydrochlorothiazide	Novartis	marketed	Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)
losartan/amlodpine	losartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)	Angiotensin II receptors (AT1) and L-type calcium channels
Valsartan (Diovan)	Valsartan (Diovan)	Radboud University Medical Center	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Allisartan Isoproxil	Allisartan Isoproxil	Guangdong Provincial People's Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
olmesartan medoxomil and a diuretic	olmesartan medoxomil and a diuretic	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker (ARB) + diuretic combination	AT1 receptor (angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

1. Chong Kun Dang Pharmaceutical · 2 drugs in this class
2. Baker Heart and Diabetes Institute · 2 drugs in this class
3. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
4. Lee's Pharmaceutical Limited · 2 drugs in this class
5. Bristol-Myers Squibb · 1 drug in this class
6. Guangdong Provincial People's Hospital · 1 drug in this class
7. Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
8. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
9. Bayer · 1 drug in this class
10. Arbor Pharmaceuticals, Inc. · 1 drug in this class